Silexion Therapeutics Files 8-K on Share and Warrant Activity
Ticker: SLXNW · Form: 8-K · Filed: May 29, 2025 · CIK: 2022416
Sentiment: neutral
Topics: corporate-action, disclosure
Related Tickers: SLXN
TL;DR
SLXN filed an 8-K detailing ordinary shares and warrants - check for dilution!
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on May 29, 2025, reporting on events related to its ordinary shares and warrants. The company, incorporated in the Cayman Islands, is based in Ramat-Gan, Israel, and trades on NASDAQ under the ticker SLXN.
Why It Matters
This filing provides updates on the company's capital structure, which can impact shareholder equity and the potential dilution from outstanding warrants.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and does not indicate immediate financial distress or significant operational changes.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- May 29, 2025 (date) — Date of report
- NASDAQ (company) — Exchange traded on
- SLXN (ticker) — Company ticker symbol
FAQ
What was Silexion Therapeutics Corp.'s former name?
Silexion Therapeutics Corp.'s former name was Biomotion Sciences.
On what date was this 8-K filing reported?
This 8-K filing was reported on May 29, 2025.
In which jurisdiction was Silexion Therapeutics Corp. incorporated?
Silexion Therapeutics Corp. was incorporated in the Cayman Islands.
What is the principal executive office address for Silexion Therapeutics Corp.?
The principal executive office address is 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606.
On which stock exchange does Silexion Therapeutics Corp. trade?
Silexion Therapeutics Corp. trades on NASDAQ.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 29, 2025 regarding Silexion Therapeutics Corp (SLXNW).